文献速递新发突发、热带与寄生虫病

四价登革热候选疫苗在儿童和成人中的长期安全性与免疫原性:随机安慰剂对照2期研究

Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.
PubMed 文献 · J Infect Dis · 2022-01-01

该2期随机安慰剂对照试验在波多黎各、哥伦比亚、新加坡和泰国登革热流行区评估TAK-003的长期安全性和免疫原性。第1部分纳入1.5-45岁受试者148人按2:1随机接种2剂TAK-003或安慰剂(间隔90天),第2部分纳入1-11岁儿童212人按3:1随机接种。第36个月时,DENV-1至DENV-4血清阳转率分别为97.3%、98.7%、88.0%和56.0%,未报告疫苗相关严重不良事件。

要点

  • TAK-003接种后36个月对4种登革热血清型仍保持中和抗体持久性。
  • DENV-4血清阳转率在基线血清阴性者中仅21.6%,显著低于血清阳性者的89.5%。
  • 未报告疫苗相关严重不良事件,耐受性良好。

核心结论

  • TAK-003在登革热流行区儿童和成人中诱导的中和抗体至少持续3年,自然感染贡献有限,且耐受性良好。

研究设计与样本

  • 2期随机安慰剂对照试验,第1部分纳入1.5-45岁受试者148人按2:1随机接种2剂TAK-003或安慰剂(间隔90天)。
  • 第2部分纳入1-11岁儿童212人按3:1随机接种TAK-003或安慰剂。
  • 第1部分评估至第36个月的中和抗体滴度,两部分均评估至第36个月的症状性登革热和严重不良事件。

主要发现

  • 第36个月时,DENV-1、DENV-2、DENV-3和DENV-4的血清阳转率分别为97.3%、98.7%、88.0%和56.0%。
  • DENV-4血清阳转率随基线血清状态显著变化:基线血清阳性者为89.5%,基线血清阴性者为21.6%。
  • 未报告疫苗相关严重不良事件。

临床怎么用

  • 在登革热流行区儿童和成人中,TAK-003接种后3年内对DENV-1至DENV-3可维持较高血清阳转率,对DENV-4的血清阳转率在基线血清阴性者中较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We report long-term safety and immunogenicity of Takeda's tetravalent dengue vaccine candidate (TAK-003) in healthy children and adults living in dengue-endemic areas in Puerto Rico, Columbia, Singapore, and Thailand. METHODS: In part 1 of this phase 2, randomized, placebo-controlled trial we sequentially enrolled 1.5-45 year olds (n = 148) into 4 age-descending groups, randomized 2:1 to receive 2 doses of TAK-003 or placebo 90 days apart. In part 2, 1-11 year olds (n = 212) were enrolled and randomized 3:1 to TAK-003 or placebo groups. We assessed neutralizing antibody titers for the 4 dengue serotypes (DENV) up to month 36 in part 1, and symptomatic dengue and serious adverse events (SAEs) up to month 36 in both parts. RESULTS: At month 36, seropositivity rates were 97.3%, 98.7%, 88.0% and 56.0% for DENV-1, -2, -3 and -4, respectively. Seropositivity rates varied significantly for DENV-4 according to serostatus at baseline (89.5% in seropositives versus 21.6% in seronegatives). No vaccine-related SAEs were reported. CONCLUSIONS: The trial demonstrated persistence of neutralizing antibody titers against TAK-003 over 3 years in children and adults living in dengue-endemic countries, with limited contribution from natural infection. TAK-003 was well tolerated. CLINICAL TRIALS REGISTRATION: NCT01511250.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sirivichayakul C, Barranco-Santana EA, Rivera IE, et al. Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study. J Infect Dis. 2022. PMID: 32658250. doi:10.1093/infdis/jiaa406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。